RosettaCommons/UTexasAptamer huggingface dataset:
Aptamer: PR10.9
Target: HIV-1 aspartyl protease (PR)
Type of nucleic acid: ssRNA
Sequence: 5'GGGUUACCUAGGAGGAGAUGCUACAUUACCUAAGUAAGAUUACGGCUUCGAGUUUAGAGACCUCUCCCUGGUAAGUGACGUCUGAACUGCUUCGAA3'
Sequence length: 96
GC content: 0.46875
Affinity: Kd: 93 ±19 nM
Pool type: 5'-GGGTTACCTAGGTGTAGATGCT-N50-AAGTGACGTCTGAACTGCTTCGAA-3' 
Pool random region: 50
Binding buffer/conditions: 20 mmol/l HEPES pH 7.4, 150 mmol/l NaCl, 5 mmol/l MgCl2
Divalent salt: MgCl
Buffer type: Other Buffers
pH: 7.4
Molecular weight of target: 22 kDa
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Therapeutic: " HIV-1 aspartyl protease (PR) plays a key role in virion morphogenesis, underscoring the effectiveness of protease inhibitors (PI). We report here, for the first time, the isolation of RNA aptamers targeted to the HIV-1 PR. Our results show that the anti-PR aptamers inhibit HIV replication, inhibition is correlated to PR-binding by aptamer in vitro and that by employing partially randomized (doped) selections, it is possible to improve the degree of inhibition of virus replication."
Additional information: *primer regions on aptamer do not match pool cited
DNA library/pool was used as a template to generate the RNA pool used in the selection. A T7 promoter sequence might be necessary to use this DNA library/pool as a template to generate the RNA pool in the selection.
Reference (2015, Mol Ther Nucleic Acids ): Duclair, S., Gautam, A., Ellington, A., & Prasad, V. R. (2015). High-affinity RNA Aptamers Against the HIV-1 Protease Inhibit Both In Vitro Protease Activity and Late Events of Viral Replication. Molecular therapy. Nucleic acids, 4(2), e228. https://doi.org/10.1038/mtna.2015.1
Aptamer: PR10.1-8E
Target: HIV-1 aspartyl protease (PR)
Type of nucleic acid: ssRNA
Sequence: 5'GGGUUACCUAGGAGGAGAUGCUCUUAAGUGUAACUUCUCAUAACAUCCGGAGGCUUUUACUUCCGGGGACCUAAGUGACGUCUGAACUGCUUCGAA3'
Sequence length: 96
GC content: 0.4791666666666667
Affinity: Kd: 17 ± 3 nM
Pool type: Doped Pool: 80% dopped pool: 5'GGGUUACCUAGGUGUAGAUGCUCUUCAUUGUAACUUCUCAUAAUUUCCCGAGGCUUUUACUUUCGGGGUCCUAAGUGACGUCUGAACUGCUUCGAA3' 
Doped pools were generated starting with the PR10.1 sequence with 20% mutations at each position across the variable 50-nucleotide region. 5'-GGGTTACCTAGGTGTAGATGCT-N50-AAGTGACGTCTGAACTGCTTCGAA-3' 
Pool random region: 50
Binding buffer/conditions: 20 mmol/l HEPES pH 7.4, 150 mmol/l NaCl, 5 mmol/l MgCl2
Divalent salt: MgCl
Buffer type: Other Buffers
pH: 7.4
Molecular weight of target: 22 kDa
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Therapeutic: " HIV-1 aspartyl protease (PR) plays a key role in virion morphogenesis, underscoring the effectiveness of protease inhibitors (PI). We report here, for the first time, the isolation of RNA aptamers targeted to the HIV-1 PR. Our results show that the anti-PR aptamers inhibit HIV replication, inhibition is correlated to PR-binding by aptamer in vitro and that by employing partially randomized (doped) selections, it is possible to improve the degree of inhibition of virus replication."
Additional information: *primer regions on aptamer do not match pool cited
DNA library/pool was used as a template to generate the RNA pool used in the selection. A T7 promoter sequence might be necessary to use this DNA library/pool as a template to generate the RNA pool in the selection.
The doped PR10.1, PR10.9, and PR10.13 RNA pools were synthesized to contain 80% WT residues and 20% non-WT residues across the 50-nt random region such that at each position there was an 80% chance that the correct nucleotide would be present and a 20% chance that one of the remaining three nucleotide would be presen
Reference (2015, Mol Ther Nucleic Acids ): Duclair, S., Gautam, A., Ellington, A., & Prasad, V. R. (2015). High-affinity RNA Aptamers Against the HIV-1 Protease Inhibit Both In Vitro Protease Activity and Late Events of Viral Replication. Molecular therapy. Nucleic acids, 4(2), e228. https://doi.org/10.1038/mtna.2015.1
Aptamer: PR10.1-8A
Target: HIV-1 aspartyl protease (PR)
Type of nucleic acid: ssRNA
Sequence: 5'GGGUUACCUAGGAGGAGAUGCUCUUAAGUGUAACUUCUCGUAAUUCCCAAGGCUUUUACCUCGGGGUCCUAAGUGACGUCUGAACUGCUUCGAA3'
Sequence length: 94
GC content: 0.4787234042553192
Affinity: Kd: 2.2 ± 0.2 nM
Pool type: Doped Pool: 80% dopped pool: 5'GGGUUACCUAGGUGUAGAUGCUCUUCAUUGUAACUUCUCAUAAUUUCCCGAGGCUUUUACUUUCGGGGUCCUAAGUGACGUCUGAACUGCUUCGAA3' 
Doped pools were generated starting with the PR10.1 sequence with 20% mutations at each position across the variable 50-nucleotide region. 5'-GGGTTACCTAGGTGTAGATGCT-N50-AAGTGACGTCTGAACTGCTTCGAA-3' 
Pool random region: 50
Binding buffer/conditions: 20 mmol/l HEPES pH 7.4, 150 mmol/l NaCl, 5 mmol/l MgCl2
Divalent salt: MgCl
Buffer type: Other Buffers
pH: 7.4
Molecular weight of target: 22 kDa
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Therapeutic: " HIV-1 aspartyl protease (PR) plays a key role in virion morphogenesis, underscoring the effectiveness of protease inhibitors (PI). We report here, for the first time, the isolation of RNA aptamers targeted to the HIV-1 PR. Our results show that the anti-PR aptamers inhibit HIV replication, inhibition is correlated to PR-binding by aptamer in vitro and that by employing partially randomized (doped) selections, it is possible to improve the degree of inhibition of virus replication."
Additional information: *primer regions on aptamer do not match pool cited
DNA library/pool was used as a template to generate the RNA pool used in the selection. A T7 promoter sequence might be necessary to use this DNA library/pool as a template to generate the RNA pool in the selection.
The doped PR10.1, PR10.9, and PR10.13 RNA pools were synthesized to contain 80% WT residues and 20% non-WT residues across the 50-nt random region such that at each position there was an 80% chance that the correct nucleotide would be present and a 20% chance that one of the remaining three nucleotide would be presen
Reference (2015, Mol Ther Nucleic Acids ): Duclair, S., Gautam, A., Ellington, A., & Prasad, V. R. (2015). High-affinity RNA Aptamers Against the HIV-1 Protease Inhibit Both In Vitro Protease Activity and Late Events of Viral Replication. Molecular therapy. Nucleic acids, 4(2), e228. https://doi.org/10.1038/mtna.2015.1
Aptamer: PR10.9-8N
Target: HIV-1 aspartyl protease (PR)
Type of nucleic acid: ssRNA
Sequence: 5'GGGUUACCUAGGAGGAGAUGCUUUGACCUAAGGUAAGAUAACGGCUUCGAGUUCAGAGACCUCGCCCUGGUAAGUGACGUCUGAACUGCUUCGAA3'
Sequence length: 95
GC content: 0.5052631578947369
Affinity: Kd: 4.3 ± 0.2 nM
Pool type: Doped Pool: 80% dopped pool: 5'GGGUUACCUAGGAGGAGAUGCUACAUUACCUAAGUAAGAUUACGGCUUCGAGUUUAGAGACCUCUCCCUGGUAAGUGACGUCUGAACUGCUUCGAA3' 
Doped pools were generated starting with the PR10.1 sequence with 20% mutations at each position across the variable 50-nucleotide region. 5'-GGGTTACCTAGGTGTAGATGCT-N50-AAGTGACGTCTGAACTGCTTCGAA-3' 
Pool random region: 50
Binding buffer/conditions: 20 mmol/l HEPES pH 7.4, 150 mmol/l NaCl, 5 mmol/l MgCl2
Divalent salt: MgCl
Buffer type: Other Buffers
pH: 7.4
Molecular weight of target: 22 kDa
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Therapeutic: " HIV-1 aspartyl protease (PR) plays a key role in virion morphogenesis, underscoring the effectiveness of protease inhibitors (PI). We report here, for the first time, the isolation of RNA aptamers targeted to the HIV-1 PR. Our results show that the anti-PR aptamers inhibit HIV replication, inhibition is correlated to PR-binding by aptamer in vitro and that by employing partially randomized (doped) selections, it is possible to improve the degree of inhibition of virus replication."
Additional information: *primer regions on aptamer do not match pool cited
DNA library/pool was used as a template to generate the RNA pool used in the selection. A T7 promoter sequence might be necessary to use this DNA library/pool as a template to generate the RNA pool in the selection.
The doped PR10.1, PR10.9, and PR10.13 RNA pools were synthesized to contain 80% WT residues and 20% non-WT residues across the 50-nt random region such that at each position there was an 80% chance that the correct nucleotide would be present and a 20% chance that one of the remaining three nucleotide would be presen
Reference (2015, Mol Ther Nucleic Acids ): Duclair, S., Gautam, A., Ellington, A., & Prasad, V. R. (2015). High-affinity RNA Aptamers Against the HIV-1 Protease Inhibit Both In Vitro Protease Activity and Late Events of Viral Replication. Molecular therapy. Nucleic acids, 4(2), e228. https://doi.org/10.1038/mtna.2015.1
Aptamer: ApPABP#11
Target: 6xHIS–LiPABP protein (rLiPABP)
Type of nucleic acid: ssDNA
Sequence: 5'GTTGCTCGTATTTAGGGCGGCCCCCTCCTCCCTCCCCCACCCGACACTATTCCCCCCCACACCAGTCTTCATCCGC3'
Sequence length: 76
GC content: 0.6447368421052632
Affinity: Kd: 10.8 ± 2.7 nM
Pool type: 5'-GCGGATGAAGACTGGTCT-40N-GTTGCTCGTATTTAGGGC-3'
Pool random region: 40
Binding buffer/conditions: 20 mM Tris-HCl pH 7.4, 1 mM MgCl2, 150 mM NaCl, 5 mM KCl, 0.2% BSA, 26°C for 30 minutes
Divalent salt: MgCl
Buffer type: Tris Buffers
pH: 7.4
Molecular weight of target: 65 kDa
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Diagnostic and Therapeutic: " Development of high-affinity molecules with the ability to recognize specifically Leishmania proteins is essential for the progress of this kind of study. Results presented here demonstrate that aptamers represent new reagents for characterization of LiPABP and that they can affect LiPABP activity. At this respect, the use of these aptamers as therapeutic tool affecting the physiological role of PABP has to be analyzed."
Additional information: *primer regions on aptamer do not match pool cited
Reference (2015, PLoS One ): Guerra-Pérez, N., Ramos, E., García-Hernández, M., Pinto, C., Soto, M., Martín, M. E., & González, V. M. (2015). Molecular and Functional Characterization of ssDNA Aptamers that Specifically Bind Leishmania infantum PABP. PloS one, 10(10), e0140048. https://doi.org/10.1371/journal.pone.0140048
Aptamer: E-CA 20
Target: M proteins on the surface of Streptococcus pyogenes (S. pyogenes)
Type of nucleic acid: ssDNA
Sequence: 5′CACACACGGAACCCCGACAACATACATACGGTGAGGGTGG3′
Sequence length: 40
GC content: 0.575
Affinity: Kd: 7±1 nM
Pool type: 5'-TTCACGGTAGCACGCATAGG-N40-CATCTGACCTCTGTGCTGCT-3'
Pool random region: 40
Binding buffer/conditions: 10 mM Tris buffer PH 8 @ (21 °C) for 60 min
Buffer type: Tris Buffers
pH: 8
Molecular weight of target: Not reported
Post-SELEX modifications: Primer region removed for this aptamer
Application as quoted in the referenced paper: Detection: " The primary objective of this work is to develop a technique that enables generation of aptamers binding to specific M-types of S. pyogenes. The improved bacterial cell-SELEX technique is successful in generating aptamers selective for S. pyogenes and some of its M-types. These aptamers are potentially useful for detecting S. pyogenes, achieving binding profiles of the various M-types, and developing new M-typing technologies for non-specialized laboratories or point-of-care testing."
Reference (2015, Methods ): Hamula, C. L., Peng, H., Wang, Z., Tyrrell, G. J., Li, X. F., & Le, X. C. (2016). An improved SELEX technique for selection of DNA aptamers binding to M-type 11 of Streptococcus pyogenes. Methods (San Diego, Calif.), 97, 51–57. https://doi.org/10.1016/j.ymeth.2015.12.005
Aptamer: E-CA 20P
Target: M proteins on the surface of Streptococcus pyogenes (S. pyogenes)
Type of nucleic acid: ssDNA
Sequence: 5′TTCACGGTAGCACGCATAGGCACACACGGAACCCCGACAACATACATACGGTGAGGGTGGCATCTGACCTCTGTGCTGCT3′
Sequence length: 80
GC content: 0.5625
Affinity: Kd: 12 ± 1 nM
Pool type: 5'-TTCACGGTAGCACGCATAGG-N40-CATCTGACCTCTGTGCTGCT-3'
Pool random region: 40
Binding buffer/conditions: 10 mM Tris buffer PH 8 @ (21 °C) for 60 min
Buffer type: Tris Buffers
pH: 8
Molecular weight of target: Not reported
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Detection: " The primary objective of this work is to develop a technique that enables generation of aptamers binding to specific M-types of S. pyogenes. The improved bacterial cell-SELEX technique is successful in generating aptamers selective for S. pyogenes and some of its M-types. These aptamers are potentially useful for detecting S. pyogenes, achieving binding profiles of the various M-types, and developing new M-typing technologies for non-specialized laboratories or point-of-care testing."
Reference (2015, Methods ): Hamula, C. L., Peng, H., Wang, Z., Tyrrell, G. J., Li, X. F., & Le, X. C. (2016). An improved SELEX technique for selection of DNA aptamers binding to M-type 11 of Streptococcus pyogenes. Methods (San Diego, Calif.), 97, 51–57. https://doi.org/10.1016/j.ymeth.2015.12.005
Aptamer: D-Cells 9
Target: M proteins on the surface of Streptococcus pyogenes (S. pyogenes)
Type of nucleic acid: ssDNA
Sequence: 5′GGGGAGGAGAAAAAGAGGACCAGAGTAACGATTCGTGGGG3′
Sequence length: 40
GC content: 0.55
Affinity: Kd: 71 ± 23 nM
Pool type: 5'-TTCACGGTAGCACGCATAGG-N40-CATCTGACCTCTGTGCTGCT-3'
Pool random region: 40
Binding buffer/conditions: 10 mM Tris buffer PH 8 @ (21 °C) for 60 min
Buffer type: Tris Buffers
pH: 8
Molecular weight of target: Not reported
Post-SELEX modifications: Primer region removed for this aptamer
Application as quoted in the referenced paper: Detection: " The primary objective of this work is to develop a technique that enables generation of aptamers binding to specific M-types of S. pyogenes. The improved bacterial cell-SELEX technique is successful in generating aptamers selective for S. pyogenes and some of its M-types. These aptamers are potentially useful for detecting S. pyogenes, achieving binding profiles of the various M-types, and developing new M-typing technologies for non-specialized laboratories or point-of-care testing."
Reference (2015, Methods ): Hamula, C. L., Peng, H., Wang, Z., Tyrrell, G. J., Li, X. F., & Le, X. C. (2016). An improved SELEX technique for selection of DNA aptamers binding to M-type 11 of Streptococcus pyogenes. Methods (San Diego, Calif.), 97, 51–57. https://doi.org/10.1016/j.ymeth.2015.12.005
Aptamer: D-Cells 9P
Target: M proteins on the surface of Streptococcus pyogenes (S. pyogenes)
Type of nucleic acid: ssDNA
Sequence: 5′TTCACGGTAGCACGCATAGGGGGGAGGAGAAAAAGAGGACCAGAGTAACGATTCGTGGGGCATCTGACCTCTGTGCTGCT3′
Sequence length: 80
GC content: 0.55
Affinity: Kd: 44 ± 8 nM
Pool type: 5'-TTCACGGTAGCACGCATAGG-N40-CATCTGACCTCTGTGCTGCT-3'
Pool random region: 40
Binding buffer/conditions: 10 mM Tris buffer PH 8 @ (21 °C) for 60 min
Buffer type: Tris Buffers
pH: 8
Molecular weight of target: Not reported
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Detection: " The primary objective of this work is to develop a technique that enables generation of aptamers binding to specific M-types of S. pyogenes. The improved bacterial cell-SELEX technique is successful in generating aptamers selective for S. pyogenes and some of its M-types. These aptamers are potentially useful for detecting S. pyogenes, achieving binding profiles of the various M-types, and developing new M-typing technologies for non-specialized laboratories or point-of-care testing."
Reference (2015, Methods ): Hamula, C. L., Peng, H., Wang, Z., Tyrrell, G. J., Li, X. F., & Le, X. C. (2016). An improved SELEX technique for selection of DNA aptamers binding to M-type 11 of Streptococcus pyogenes. Methods (San Diego, Calif.), 97, 51–57. https://doi.org/10.1016/j.ymeth.2015.12.005
Aptamer: E-Cells 1P
Target: M proteins on the surface of Streptococcus pyogenes (S. pyogenes)
Type of nucleic acid: ssDNA
Sequence: 5′TTCACGGTAGCACGCATAGGGGGGAGGAGAAAAGAGGACCAGAGTAACGATTCGTGGGGCATCTGACCTCTGTGCTGCT3′
Sequence length: 79
GC content: 0.5569620253164557
Affinity: Kd: 20 ± 3 nM
Pool type: 5'-TTCACGGTAGCACGCATAGG-N40-CATCTGACCTCTGTGCTGCT-3'
Pool random region: 40
Binding buffer/conditions: 10 mM Tris buffer PH 8 @ (21 °C) for 60 min
Buffer type: Tris Buffers
pH: 8
Molecular weight of target: Not reported
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Detection: " The primary objective of this work is to develop a technique that enables generation of aptamers binding to specific M-types of S. pyogenes. The improved bacterial cell-SELEX technique is successful in generating aptamers selective for S. pyogenes and some of its M-types. These aptamers are potentially useful for detecting S. pyogenes, achieving binding profiles of the various M-types, and developing new M-typing technologies for non-specialized laboratories or point-of-care testing."
Reference (2015, Methods ): Hamula, C. L., Peng, H., Wang, Z., Tyrrell, G. J., Li, X. F., & Le, X. C. (2016). An improved SELEX technique for selection of DNA aptamers binding to M-type 11 of Streptococcus pyogenes. Methods (San Diego, Calif.), 97, 51–57. https://doi.org/10.1016/j.ymeth.2015.12.005
Aptamer: PL1
Target: Pancreatic ductal adenocarcinoma cell line (PL45)
Type of nucleic acid: ssDNA
Sequence: 5′CGCTCGGATGCCACTACAGTGCTAATCTCAAGGGTCGTTCCCGATCACCGAGTCTGAGGCTGG3′
Sequence length: 63
GC content: 0.5873015873015873
Affinity: Kd: 24.9 ± 3.6 nM @37C
Pool type: 5′-CCAGCCTCAGACTCGGTGA-N25-TGTAGTGGCATCCGAGCG-3′
Pool random region: 25
Binding buffer/conditions: Dulbecco's phosphate buffered saline, glucose (4.5 g/L), 5 mM MgCl2, bovine serum albumin (1 mg/mL) and Transfer ribonucleotide acid (tRNA) (0.1 mg/mL)
Divalent salt: MgCl
Buffer type: PBS/phosphate buffers
pH: 7.4
Molecular weight of target: Not reported
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Diagnostic and Therpeutic: " Pancreatic cancer costs nearly 40,000 lives in the U.S. each year and has one of the lowest survival rates among cancers. Effective treatment of pancreatic ductal adenocarcinoma is hindered by lack of a reliable biomarker. The results show a viability of almost 80% for negative cells while only 50% of the target cells remained alive after 48 h incubation. These results lead to the conclusion that further research could reveal protein biomarkers specific to pancreatic adenocarcinoma, with probes available for early detection."
Reference (2015, Sci Rep ): Champanhac, C., Teng, I. T., Cansiz, S., Zhang, L., Wu, X., Zhoa, Z., Fu, T., & Tan, W. (2015). Development of a panel of DNA Aptamers with High Affinity for Pancreatic Ductal Adenocarcinoma. Scientific reports, 5, 16788. https://doi.org/10.1038/srep16788
Aptamer: PL2
Target: Pancreatic ductal adenocarcinoma cell line (PL45)
Type of nucleic acid: ssDNA
Sequence: 5′CGCTCGGATGCCACTACAGGAACTAACACACTACTGAACCGTGCTCACCGAGTCTGAGGCTGG3′
Sequence length: 63
GC content: 0.5714285714285714
Affinity: Kd: 20.9 ± 3.5 nM @ 37C
Pool type: 5′-CCAGCCTCAGACTCGGTGA-N25-TGTAGTGGCATCCGAGCG-3′
Pool random region: 25
Binding buffer/conditions: Dulbecco's phosphate buffered saline, glucose (4.5 g/L), 5 mM MgCl2, bovine serum albumin (1 mg/mL) and Transfer ribonucleotide acid (tRNA) (0.1 mg/mL)
Divalent salt: MgCl
Buffer type: PBS/phosphate buffers
pH: 7.4
Molecular weight of target: Not reported
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Diagnostic and Therpeutic: " Pancreatic cancer costs nearly 40,000 lives in the U.S. each year and has one of the lowest survival rates among cancers. Effective treatment of pancreatic ductal adenocarcinoma is hindered by lack of a reliable biomarker. The results show a viability of almost 80% for negative cells while only 50% of the target cells remained alive after 48 h incubation. These results lead to the conclusion that further research could reveal protein biomarkers specific to pancreatic adenocarcinoma, with probes available for early detection."
Reference (2015, Sci Rep ): Champanhac, C., Teng, I. T., Cansiz, S., Zhang, L., Wu, X., Zhoa, Z., Fu, T., & Tan, W. (2015). Development of a panel of DNA Aptamers with High Affinity for Pancreatic Ductal Adenocarcinoma. Scientific reports, 5, 16788. https://doi.org/10.1038/srep16788
Aptamer: PL3
Target: Pancreatic ductal adenocarcinoma cell line (PL45)
Type of nucleic acid: ssDNA
Sequence: 5′CGCTCGGATGCCACTACAGCACTCACCTCAAGGGTTCCGTGTCACCGAGTCTGAGGCTGG3′
Sequence length: 60
GC content: 0.6166666666666667
Affinity: Kd: 23.1 ± 5.3 nM @37C
Pool type: 5′-CCAGCCTCAGACTCGGTGA-N25-TGTAGTGGCATCCGAGCG-3′
Pool random region: 25
Binding buffer/conditions: Dulbecco's phosphate buffered saline, glucose (4.5 g/L), 5 mM MgCl2, bovine serum albumin (1 mg/mL) and Transfer ribonucleotide acid (tRNA) (0.1 mg/mL)
Divalent salt: MgCl
Buffer type: PBS/phosphate buffers
pH: 7.4
Molecular weight of target: Not reported
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Diagnostic and Therpeutic: " Pancreatic cancer costs nearly 40,000 lives in the U.S. each year and has one of the lowest survival rates among cancers. Effective treatment of pancreatic ductal adenocarcinoma is hindered by lack of a reliable biomarker. The results show a viability of almost 80% for negative cells while only 50% of the target cells remained alive after 48 h incubation. These results lead to the conclusion that further research could reveal protein biomarkers specific to pancreatic adenocarcinoma, with probes available for early detection."
Reference (2015, Sci Rep ): Champanhac, C., Teng, I. T., Cansiz, S., Zhang, L., Wu, X., Zhoa, Z., Fu, T., & Tan, W. (2015). Development of a panel of DNA Aptamers with High Affinity for Pancreatic Ductal Adenocarcinoma. Scientific reports, 5, 16788. https://doi.org/10.1038/srep16788
Aptamer: PL4
Target: Pancreatic ductal adenocarcinoma cell line (PL45)
Type of nucleic acid: ssDNA
Sequence: 5′CGCTCGGATGCCACTACAGGGACTAAGCACACTACTGTTCACGGTCACCGAGTCTGAGGCTGG3′
Sequence length: 63
GC content: 0.5873015873015873
Affinity: Kd: 11.9 ± 1.4 nM @37C
Pool type: 5′-CCAGCCTCAGACTCGGTGA-N25-TGTAGTGGCATCCGAGCG-3′
Pool random region: 25
Binding buffer/conditions: Dulbecco's phosphate buffered saline, glucose (4.5 g/L), 5 mM MgCl2, bovine serum albumin (1 mg/mL) and Transfer ribonucleotide acid (tRNA) (0.1 mg/mL)
Divalent salt: MgCl
Buffer type: PBS/phosphate buffers
pH: 7.4
Molecular weight of target: Not reported
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Diagnostic and Therpeutic: " Pancreatic cancer costs nearly 40,000 lives in the U.S. each year and has one of the lowest survival rates among cancers. Effective treatment of pancreatic ductal adenocarcinoma is hindered by lack of a reliable biomarker. The results show a viability of almost 80% for negative cells while only 50% of the target cells remained alive after 48 h incubation. These results lead to the conclusion that further research could reveal protein biomarkers specific to pancreatic adenocarcinoma, with probes available for early detection."
Reference (2015, Sci Rep ): Champanhac, C., Teng, I. T., Cansiz, S., Zhang, L., Wu, X., Zhoa, Z., Fu, T., & Tan, W. (2015). Development of a panel of DNA Aptamers with High Affinity for Pancreatic Ductal Adenocarcinoma. Scientific reports, 5, 16788. https://doi.org/10.1038/srep16788